SELENOP and Alzheimer disease: In conclusion, results of our case–control study indicate that concentrations of selenoprotein P in the CSF are decreased in ALS and increased in AD and MCI, thus suggesting alterations of the overall selenium availability in the brain and/or deleterious effects of abnormal selenoprotein P concentrations.